title: Review of the clinical experience with a modified release form of tacrolimus [FK506E (MR4)] in transplantation.
abstract: Non-compliance in solid transplantation recipients is a major factor in acute graft rejection, which influences patient survival. Nowadays, tacrolimus is one of the most widely used immunosuppressant agents together with cyclosporine following kidney and liver transplantation with a standardized twice-daily dosing regimen. To improve the patients' compliance to the prescribed immunosuppressive therapy, FK506E (MR4), a modified release (MR) oral dosage form of tacrolimus has been developed for a once-daily dosing regimen. This report reviews the most recent results of clinical trials with MR tacrolimus after kidney and liver transplantation.
authors.affiliation: Department of General Surgery, Ruprecht-Karls-University, Heidelberg, Heidelberg, Germany.
authors.forename: Moritz N
authors.initials: MN
authors.lastname: Wente
authors.forename: Peter
authors.initials: P
authors.lastname: Sauer
authors.forename: Arianeb
authors.initials: A
authors.lastname: Mehrabi
authors.forename: Jürgen
authors.initials: J
authors.lastname: Weitz
authors.forename: Markus W
authors.initials: MW
authors.lastname: Büchler
authors.forename: Jan
authors.initials: J
authors.lastname: Schmidt
authors.forename: Peter
authors.initials: P
authors.lastname: Schemmer
mesh_terms: D003692:Delayed-Action Preparations; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D016030:Kidney Transplantation; D016031:Liver Transplantation; D016559:Tacrolimus / Q000008:administration & dosage*
chemical_list: D003692:Delayed-Action Preparations; D007166:Immunosuppressive Agents; D016559:Tacrolimus